Director
Thermo Fisher Scientific
Richmond, Virginia
Amy Lavelle, Ph.D., is Director of Labs at Thermo Fisher Scientific (PPD Clinical Research). She received her Ph.D. in Human and Molecular Genomics from Virginia Commonwealth University, School of Medicine in 2009. She started her career as a molecular scientist at Commonwealth Biotechnologies, Inc. and, after receiving her doctorate, began at PPD in the Immunochemistry Research and Development department, focusing on large molecule bioanalysis. There she moved from Principal Investigator to Associate Director, managing a team of research scientists supporting LBA method transfer, development and validation of novel biologics, particularly ADCs, and commercial and novel biomarker GLP-like validations and non-GLP qualifications. She is currently the Director of the Molecular Genomics and Flow Cytometry Departments, focusing on development, validation and analysis of PCR-based assays for cell and gene therapies and mRNA-based therapies and flow cytometry. Amy is also part of a cross-functional Cell and Gene Therapy Task Force, focusing on strategy for the Clinical Research Group at Thermo Fisher Scientific. Amy’s expertise in regulated bioanalysis has resulted in a number of publications and presentations, most notably focused on immunogenicity and cell and gene therapy. Amy supports women in STEM as global lead for Thermo Fisher Scientific’s Women’s Empowerment BRG.
Disclosure information not submitted.
Symposium: Bioanalytical Lab Innovations 1
Monday, October 21, 2024
9:00 AM – 11:00 AM MT